Can a simple vaccine keep COPD patients out of the hospital?

NCT ID NCT07640841

Not yet recruiting Prevention Sponsor: Jiangsu Province Centers for Disease Control and Prevention Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This large trial will study whether flu and pneumonia vaccines can reduce serious flare-ups and medical costs in people aged 45-80 with COPD. About 7,000 participants will be split into four groups: flu vaccine, pneumonia vaccine, both, or no vaccine. Researchers will track lung function and flare-ups over 12 months to see if vaccination makes a real difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trivalent Influenza Vaccine (inactivated) and 23-valent Pneumococcal Polysaccharide Vaccine
What this could lead to: If successful, this could show that routine flu and pneumonia vaccines help prevent COPD flare-ups and reduce healthcare costs for patients.
What could go wrong: This is a Phase 4 trial, so the vaccines are already approved. The main uncertainty is whether they provide meaningful benefit specifically for COPD patients. The open-label design may introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease pneumonia influenza prevention target pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA AND PNEUMONIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.